Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ivosidenib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463768
What this trial is testing

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia
French Innovative Leukemia Organisation 60
Early research (Phase 1)Ended earlyNCT04088188
What this trial is testing

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Who this might be right for
Advanced CholangiocarcinomaMetastatic CholangiocarcinomaUnresectable Cholangiocarcinoma
Academic and Community Cancer Research United 8
Testing effectiveness (Phase 2)Study completedNCT04056910
What this trial is testing

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Who this might be right for
Advanced Solid TumorIDH1 MutationGlioma
Jason J. Luke, MD 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922
What this trial is testing

Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Celgene 130
Early research (Phase 1)Looking for participantsNCT02074839
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more
Institut de Recherches Internationales Servier 291
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Study completedNCT03343197
What this trial is testing

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 49
Not applicableWithdrawnNCT06648473
What this trial is testing

Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Who this might be right for
Low Grade Glioma of Brain
Duke University
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Early research (Phase 1)Looking for participantsNCT05010772
What this trial is testing

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Who this might be right for
Acute Myeloid Leukemia
M.D. Anderson Cancer Center 125
Not applicableApproved For MarketingNCT03245424
What this trial is testing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Who this might be right for
Acute Myeloid LeukemiaRelapsed Adult AMLRelapsed Pediatric AML
Agios Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07282262
What this trial is testing

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Who this might be right for
Biliary Tract Cancer
Peking Union Medical College Hospital 300
Not applicableLooking for participantsNCT06607302
What this trial is testing

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Who this might be right for
Cholangiocarcinoma
iOMEDICO AG 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06081829
What this trial is testing

Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Who this might be right for
Cholangiocarcinoma Non-resectableCholangiocarcinoma Metastatic
Servier 12